Clinical Trial Update: CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating CD19 CAR-T cells for relapse or refractory CD19-positive B-cell acute lymphoblastic leukemia. The current status of the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CD19 CAR T cells

Snippet

Sponsor: Henan Cancer Hospital | Conditions: B-cell Acute Lymphocytic Leukemia | Phase 1, Phase 2 | Status: UNKNOWN